MedTech Global Insights

In this episode of MedTech Global Insights, we dissect the immense challenges and strategic implications of the European Union's In Vitro Diagnostic Regulation (IVDR). With transition deadlines looming, a critical bottleneck in Notified Body capacity is putting thousands of products at risk of being forced off the market. We explore what this regulatory shift really means for manufacturers worldwi...

The U.S. FDA just released pivotal new draft guidance for AI and Machine Learning-enabled medical devices, creating new challenges and opportunities for manufacturers. This episode of MedTech Global Insights provides a concise breakdown of what this policy means for the industry and your product strategy. We explore the specific requirements of the new predetermined change control plans and what t...

The U.S. FDA has finalized its rule to regulate laboratory-developed tests (LDTs) as medical devices, ending decades of enforcement discretion. This landmark decision imposes significant new requirements on clinical laboratories, aligning them with traditional IVD manufacturers and creating a new set of complex challenges for market access and compliance. This shift will require labs to navigate a...

This week, we dive into the new medical device regulatory reliance pilot program launched between Malaysia and Thailand. This collaboration creates a powerful fast-track for market access in the ASEAN region, allowing companies to leverage an approval in one country to accelerate registration in the other, but the pathway is filled with critical nuances. We explore how this program fundamentally c...

Last week, the U.S. FDA began strict enforcement of new cybersecurity rules for medical devices, catching many global manufacturers by surprise. This sudden shift requires a complete software bill of materials (SBOM) and a proactive security plan, leading to submission rejections and significant market delays for unprepared companies. This episode of MedTech Global Insights dives into the immediat...

The U.S. FDA has drawn a new line in the sand for MedTech innovators. With its "refuse to accept" policy now in effect for 510(k) submissions lacking robust cybersecurity measures, the rules for market entry have fundamentally changed. This episode breaks down the new mandatory requirements, including the crucial Software Bill of Materials (SBOM) and post-market surveillance plans that are now non...

The European Union has once again extended the transition deadlines for the In Vitro Diagnostic Regulation (IVDR), creating both relief and confusion for diagnostic manufacturers. This episode of MedTech Global Insights breaks down what this latest delay really means for the industry and your business strategy. We go beyond the headlines to explore the strategic dilemmas facing companies. Is this...

In the last week of March, the US FDA dramatically escalated its cybersecurity requirements for wirelessly connected medical devices, creating new, complex hurdles for manufacturers. This move signals a major shift from passive checklists to demands for proactive threat management, catching many international companies unprepared and threatening their access to the world's largest MedTech market....

This week on MedTech Global Insights, we dissect the FDA's groundbreaking announcement of a new AI-powered platform for monitoring adverse events. This move signals a seismic shift from reactive to proactive post-market surveillance, creating a new set of complex challenges for medical device manufacturers. We explore the hidden data burdens this new system imposes. For instance, a European manufa...

The U.S. FDA has just redefined the rules for AI-powered medical software, shifting from one-time approvals to demanding continuous, real-world performance data. This new 'Lifecycle Assurance' approach signals a global trend towards total product lifecycle regulation, creating urgent challenges for MedTech innovators. This episode of MedTech Global Insights unpacks what this means for device manuf...

The U.S. FDA just reclassified a key category of optical diagnostic devices, a move that reshaped the competitive landscape for the entire ophthalmic tech industry last week. This is not just a minor regulatory update; it is a fundamental shift that could either fast-track your product to market or unleash a flood of new, agile competitors. In this episode, we dissect the FDA's final order and its...

The U.S. FDA has quietly dropped a bombshell on the AI medical device industry. A new draft guidance is set to redefine what "post-market surveillance" means for software, creating a complex and costly new reality for innovators. This episode dives into the critical shift from focusing on pre-market approval to the necessity of continuous, real-world performance monitoring. We explore the challeng...

In this episode of MedTech Global Insights, we unpack the most significant regulatory shift in Southeast Asia this year. The costly and time-consuming process of seeking individual device approvals in each country is being replaced by a powerful new trend: regulatory reliance. We dive into the new pilot program between Malaysia and Thailand that is creating an expedited pathway for market access....

The European Union is taking decisive action to combat the critical shortage of medical devices, a problem that has plagued its healthcare systems since the rollout of MDR. This episode unpacks the European Commission's new proposal for a mandatory six-month notification period for discontinuing devices, and what it means for manufacturers. This isn't just another form to fill out. it's a fundamen...

This week, MedTech Global Insights explores the seismic shift in European regulations for AI-powered medical devices. A major EU Notified Body has dropped a new, mandatory cybersecurity guidance document, sending shockwaves through the industry by demanding retroactive compliance. We unpack what this means for manufacturers, from agile startups to global giants. We explore the stringent new requir...

The FDA has officially replaced the long-standing QSIT inspection model with a new approach under the Quality Management System Regulation (QMSR). This shift towards harmonization with ISO 13485 introduces a more holistic, risk-based auditing process, catching many MedTech manufacturers off guard and rendering their old preparation methods obsolete. This episode of MedTech Global Insights dives in...

This week, MedTech Global Insights dives into the most significant U.S. regulatory shift of 2026: the FDA's new Quality Management System Regulation (QMSR). We uncover why this is far more than a simple alignment with international standards and exposes a new level of corporate liability. The episode reveals how FDA inspectors now have unprecedented access to high-level management review meetings....

The FDA's "honeymoon phase" for medical device cybersecurity is over. In this episode, we dissect the agency's heightened scrutiny on premarket submissions, moving beyond simple documentation to active verification. We explore the new, unwritten rules manufacturers must follow to avoid costly rejections. We look at the case of a company whose 510(k) submission was delayed for months. Despite provi...

The FDA has drawn a new line in the sand for medical device market access, and non-compliance means immediate rejection. With the full implementation of Section 524B of the FD&C Act, robust cybersecurity documentation is no longer optional for any 510(k) submission of a connected "cyber device." This episode breaks down the critical new requirements that are already impacting market entry timeline...

This week on MedTech Global Insights, we dissect the groundbreaking new draft guidance from the U.S. FDA on AI and Machine Learning medical devices. This pivotal announcement introduces new requirements for adaptive algorithms, fundamentally changing the regulatory landscape for software as a medical device (SaMD) manufacturers worldwide. We explore what the new "Predetermined Change Control Plan"...

This week, MedTech Global Insights explores a critical challenge for international manufacturers entering the U.S. market. We analyze the recent case of a leading Japanese robotics firm whose 510(k) submission for an innovative surgical system was rejected by the FDA. The cause was not clinical failure, but non-compliance with new digital submission standards and cybersecurity protocols. This epis...

This week on MedTech Global Insights, we dive into a crucial, under-the-radar development from the U.S. FDA. We explore the recent clearance of an AI-powered triage tool for stroke detection and what this single approval reveals about the future of AI regulation in American healthcare. We move beyond the hype of algorithms and predictive accuracy to uncover the real challenges and expectations the...

The clock is ticking on a major regulatory shift in the European Union. With the mandatory use of key EUDAMED modules fast approaching, the era of radical transparency for medical devices is here. This isn't just a compliance update; it's a fundamental change that exposes manufacturers to new levels of public and competitor scrutiny, where every piece of data is visible to the world. This episode...

The U.S. FDA is changing the rules for AI in medical devices, promising faster innovation. This new framework allows for pre-approved algorithm updates, potentially slashing go-to-market timelines. But this speed comes with a cost. This episode of MedTech Global Insights unpacks the FDA's new guidance on Predetermined Change Control Plans (PCCPs). We explore how this shifts the regulatory burden f...

The European IVDR continues to challenge MedTech manufacturers with inconsistent interpretations and sudden shifts in compliance requirements. This episode dives into a recent and critical development: the "silent reclassification" of certain diagnostic software, which is forcing companies to pull products from the market and re-evaluate their entire regulatory strategy. We explore a case study of...